|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.55 HKD | -0.92% |
|
+8.95% | +5.38% |
| Apr. 26 | Central Bank, Tech Outlooks Lift Major Asian Stock Markets | MT |
| Apr. 16 | Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets | MT |
(Reuters) - Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine, priming it for possible speedy regulatory approvals.
Moderna and AstraZeneca are close behind and are likely to have early data on their vaccine candidates before the end of the year. More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 42 in human trials, according to the World Health Organization (WHO).
(Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy and Vishwadha Chander in Bengaluru; editing by Ankur Banerjee, Maju Samuel, Ramakrishnan M. and Sriraj Kalluvila)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,988 GBX | -0.32% | +9.84% | 233B | ||
| 108 USD | +1.69% | +3.36% | 40.65B | ||
| 87.21 USD | +0.58% | -0.91% | 20.9B | ||
| 25.4 USD | +0.55% | -2.31% | 143B | ||
| 6.47 USD | -0.31% | -.--% | 642M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +5.38% | 8.67B | |
| +17.35% | 70.95B | |
| +6.69% | 8.16B | |
| -20.96% | 7.91B | |
| +0.49% | 4.51B | |
| +17.12% | 4.31B | |
| -3.38% | 4.07B | |
| -2.61% | 3.84B | |
| +22.08% | 3.63B | |
| +7.96% | 3.26B |
SINOPHARM GROUP CO. LTD. 
